Top Story

Ceftolozane/tazobactam shows promise against gram-negative infections

October 21, 2014

PHILADELPHIA — Phase 3 study data indicate the novel combination antibiotic ceftolozane/tazobactam achieved high clinical and microbiological cure rates in patients with complicated urinary tract infections and complicated intra-abdominal infections caused by extended-spectrum beta-lactamase–producing pathogens.

According to Steven Gilman, PhD, executive vice president of research and development and chief scientific officer of Cubist, there have been no new agents approved for gram-negative infections since the 10 x ’20 imitative was launched in 2010. He said there are roughly 25,000 deaths in the US and Europe each year from drug-resistant bacteria.

figure Meeting News CoverageVideo

Integrase inhibitors favorable as initial HIV therapy

October 20, 2014
PHILADELPHIA — Joel Gallant, MD, MPH, of the Southwest Care Center in Santa Fe, N.M., and outgoing chair of the HIVMA, gives an overview of his talk at IDWeek…

10 economic consequences of the Ebola crisis

October 20, 2014
The 2014 Ebola outbreak is the deadliest in recorded history, with 8,997 cases and 4,493 deaths reported by WHO as of Oct. 16. Recent infection of health care workers in…
Worth Building

Follow a checklist to help decide what to do with estate life insurance

October 20, 2014
Before recent changes in estate laws, it was common for attorneys, financial planners and insurance agents to recommend purchasing life insurance — commonly called…
More News Headlines »
CME
figure

HCV Consults: Volume 1, Number 3

This activity is supported by educational grants from AbbVie and Genentech, Inc.

More »
Meeting News Coverage Video
figure

Integrase inhibitors favorable as initial HIV therapy

October 20, 2014
PHILADELPHIA — Joel Gallant, MD, MPH, of the Southwest Care Center in Santa Fe, N.M., and outgoing chair of the…
More »
CME
figure

HCV Consults: Volume 1, Number 1

This activity is supported by educational grants from AbbVie and Genentech.

Physicians seldom experience a paradigm shift in disease management as great as that transpiring in HCV therapy. With…
More »